| 000 | 01709 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515091222.0 | ||
| 264 | 0 | _c20080219 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a1219-4956 | ||
| 024 | 7 |
_a10.1007/BF02893497 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeser, Asli Rehber | |
| 245 | 0 | 0 |
_aHER-2, TOP2A and chromosome 17 alterations in breast cancer. _h[electronic resource] |
| 260 |
_bPathology oncology research : POR _c2007 |
||
| 300 |
_a180-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnthracyclines _xtherapeutic use |
| 650 | 0 | 4 |
_aAntigens, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aChromosomes, Human, Pair 17 _xgenetics |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type II _xgenetics |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xgenetics |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Amplification _xgenetics |
| 650 | 0 | 4 | _aGene Deletion |
| 650 | 0 | 4 |
_aGene Dosage _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Situ Hybridization, Fluorescence |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPoly-ADP-Ribose Binding Proteins |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xgenetics |
| 700 | 1 | _aTuzlali, Sitki | |
| 700 | 1 | _aGuzey, Deniz | |
| 700 | 1 | _aDolek Guler, Semra | |
| 700 | 1 | _aHacihanefioglu, Seniha | |
| 700 | 1 | _aDalay, Nejat | |
| 773 | 0 |
_tPathology oncology research : POR _gvol. 13 _gno. 3 _gp. 180-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02893497 _zAvailable from publisher's website |
| 999 |
_c17443299 _d17443299 |
||